Genenta Science S.p.A. logo

Genenta Science S.p.A. (K5F)

Market Open
12 Jun, 20:00
XFRA XFRA
1. 57
+0.03
+1.9481%
- Market Cap
- P/E Ratio
- Div Yield
100 Volume
0 Eps
1.54
Previous Close
Add Transaction
Day Range
1.57 1.57
Year Range
0.42 3.92
Want to track K5F and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

K5F trading today higher at €1.57, an increase of 1.9481% from yesterday's close, completing a monthly increase of 93.8272% or €0.76. Over the past 12 months, K5F stock gained 28.6885%.
K5F is not paying dividends to its shareholders.
The last earnings report, released on Mar 27, 2026, exceeded the consensus estimates by 0.3641%. On average, the company has surpassed earnings expectations by 0.3641%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

K5F Chart

Genenta Science S.p.A. (K5F) FAQ

What is the stock price today?

The current price is €1.57.

On which exchange is it traded?

Genenta Science S.p.A. is listed on XFRA.

What is its stock symbol?

The ticker symbol is K5F.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Genenta Science S.p.A. ever had a stock split?

No, there has never been a stock split.

Genenta Science S.p.A. Profile

Biotechnology Industry
Healthcare Sector
Pierluigi Paracchi CEO
XFRA Exchange
US36870W1009 ISIN
IT Country
13 Employees
- Last Dividend
- Last Split
15 Dec 2021 IPO Date

Overview

Genenta Science S.p.A. is a pioneering clinical-stage biotechnology company based in Italy, focusing on the development of innovative hematopoietic stem cell gene therapies aimed at treating solid tumors. Established in 2014 and having its headquarters in Milan, Genenta Science has made significant strides in the biotechnology field, particularly in gene therapy research. The company's mission revolves around exploiting the potential of gene manipulation in hematopoietic stem cells to create therapies that can effectively target and eliminate solid tumors, offering new hope for patients suffering from hard-to-treat cancers.

Products and Services

  • Temferon

    Genenta’s forefront product, Temferon, represents a cutting-edge development in the field of gene therapies for cancer treatment. Currently, in Phase 1/2a clinical trials, Temferon is designed for the treatment of glioblastoma multiforme in patients with an unmethylated MGMT gene promoter. This innovative therapy leverages the power of gene manipulation to target and destroy tumor cells, offering a novel approach in combating one of the most aggressive forms of brain cancer.

  • Expansion into Other Solid Tumor Indications

    Beyond glioblastoma multiforme, Genenta is exploring the potential of Temferon in treating other solid tumors. This includes locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. The expansion of Temferon's application showcases Genenta’s commitment to diversifying its therapeutic solutions, aiming to provide targeted and effective treatments for a broader range of solid tumors.

  • Biologic Platform Development

    Apart from Temferon, Genenta Science is developing a biologic platform tailored to deliver immunomodulatory molecules directly into tumors by exploiting monocytes/macrophages that infiltrate cancers. This innovative approach seeks to enhance the precision and efficacy of cancer treatment, by turning the tumor’s own environment against it. It represents a promising advancement in the fight against cancer, offering a novel strategy to bolster the body’s immune response against tumors.

Contact Information

Address: Via Olgettina No. 58
Phone: 39 02 26 43 46 81